Abstract #4961
Parameters associated with durable clinical success in a multi-center trial using MR guided focused ultrasound treat uterine leiomyomas
Rachel Bitton1, Angela Fast2, Gina Hesley3, Steven Raman4, Alan Matsumoto5, Eric Dolan6, Maureen Kohi7, Thomas Price8, Fiona Fenessey9, and Pejman Ghanouni1
1Radiology, Stanford University, Stanford, CA, United States, 2Allegheny Health Network, Pittsburgh, PA, United States, 3Radiology, Mayo Clinic, Rochester, MN, United States, 4Radiology, UCLA, Los Angeles, CA, United States, 5Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, United States, 6Interventional Radiology, Ohio Health, Columbus, OH, United States, 7Radiology, UCSF, San Francisco, CA, United States, 8Obstetrics and Gynecology, Duke University, Durham, NC, United States, 9Radiology, Brigham and Women's Hospital, Boston, MA, United States
Synopsis
This study presents results of a prospective multicenter clinical trial of 99 women treated with MR guided focused ultrasound (MRgFUS) for symptomatic uterine leiomyomas to assess treatment durability and to evaluate potential demographic, imaging, and technical characteristics associated with lasting clinical outcomes. Following treatment, there was an improvement in symptoms, with a significant decrease in mean symptom severity score at the 6, 12, 24 and 36 month follow up (p<0.001). In a multivariate model, a new parameter of interest, the ratio of non-perfused volume to total fibroid volume (NPV/TFV) was found to be predictive of durable clinical success (p=0.03).
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
